Expression of human epidermal growth factor receptor type 2 (HER2) in head and neck squamous cell carcinoma (HNSCC) cell line HN5 can be employed with great opportunities of success for specific targeting of anti-cancer chemotherapeutic agents. In the current study, HER2-specific affibody molecule, ZHER2:342 (an engineered protein with great affinity for HER2 receptors) was selected for conjugation to idarubicin (an anti-neoplastic antibiotic). ZHER2:342 affibody gene with one added cysteine code at the its 5' end was synthesized de novo and then inserted into pET302 plasmid and transferred to E. Coli BL21 hosting system. After induction of protein expression, the recombinant ZHER2 affibody molecules were purified using Ni-NTA resin and purity was analyzed through SDS-PAGE. Affinity-purified affibody molecules were conjugated to idarubicin through a heterobifunctional crosslinker, sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC). Specific toxicity of idarubicin-ZHER2 affibody conjugate against two HER2-positive cells, HN5 and MCF7 was assessed through MTT assay after an exposure time of 48 hours with different concentrations of conjugate. Idarubicin in the non-conjugated form showed potent toxic effects against both cell lines, while HN5 cells were significantly more sensitive compared to MCF-7 cells. Dimeric ZHER2 affibody showed a mild decreasing effect on growth of both HN5 and MCF-7 cells at optimum concentration. Idarubicin-ZHER2 affibody conjugate at an optimum concentration reduced viability of HN5 cell line more efficiently compared to MCF-7 cell line. In conclusion, idarubicin-ZHER2 affibody conjugate in optimum concentrations can be used for specific targeting and killing of HN5 cells.
Idarubicin, Z HER2 affibody, Idarubicin-Z HER2 affibody conjugate, Ovarian Cancer
Scan to discover onlineBackground & Objective: Overexpression of human epidermal growth factor receptor 2 (HER2) causes cell transformation and development of various types of malignancies. Idarubicin is an effective anti-neoplastic drug but its specific delivery to the targeted cells is still a great challenge. Affibody as a cost-effective peptide molecule with low molecular weight has a high affinity for HER2 receptors. Breast and ovarian cancers as wide speared types of malignancies are associated with high expression of HER2. In the current study, we assessed the cytotoxic effects of idarubicin-ZHER2 affibody conjugate on the positive-HER2 cancer cell lines.Methods: The cytotoxic effects of constructed idarubicin-ZHER2 affibody conjugate on the SK-BR-3, SK-OV-3, and MCF-7 cells with various levels of HER2 expression were evaluated by MTT assay following 48 hours of incubation.Results: Idarubicin showed a potent and dose-dependent cytotoxic effect against all treated cell lines while the SK-OV-3 cells were significantly more sensitive. The dimeric form of the ZHER2 affibody molecule showed a mild effect on the cell viability of all treated cells at its optimum concentration. The constructed Idarubicin-ZHER2 affibody conjugate decreased the viability of SK-OV-3 cells at its optimal concentration, more efficiently and specifically than other treated cells.
Conclusion:The ZHER2-affibody conjugate of idarubicin has a more specific cytotoxic effect compared with idarubicin alone against HER2-overexpressing ovarian cancerous cells. It appears the ZHER2-affibody conjugate of idarubicin has great potential to be implicated as an innovative anti-cancer agent in future clinical trials in patients with HER2-overexpressing ovarian cancer.
Background:
Chemotherapy is a routine approach in treatment of patients with cancer,
while side effects of chemotherapeutic drugs are inevitable. To minimize side effects, specific targeting
of neoplastic cells is a promising strategy in cancer therapy. Sodium arsenite is a metalloid
toxin with anti-neoplastic properties, but low selectivity and carcinogenic activity have limited its
clinical usage.
Methods:
Targeting of HER2-overexpressing (SK-BR-3) and HER2-low expressing (MCF-7) cancerous
breast cell lines by two different liposomal forms of sodium arsenite (bare liposome and
trastuzumab-conjugated liposome) was investigated in the current study. Levels of HER2 expression
in the above mentioned cell lines were confirmed by western blotting. Size and morphology of
the constructed liposomes were characterized by atomic force microscopy (AFM) and dynamic light
scattering (DLS). Viability of the cells after treatment was assessed using MTT assay.
Results:
Sodium arsenite in the free and liposomal forms showed growth inhibitory effects against
both SK-BR-3 and MCF-7 cell lines in an examined concentration range of 1-20 µM, although this
effect was more significant in SK-BR-3 cell line. Loading of sodium arsenite in anti-HER2 immunoliposomes
significantly enhanced its cytotoxicity while the specificity was also improved. By
encapsulation of sodium arsenite in anti-HER2 immunoliposomes, its efficacy in ablation of SKBR-
3 cells was increased about 1.4-fold compared to the free or liposomal forms.
Conclusion:
In conclusion, targeted delivery of sodium arsenite using anti-HER2 immunoliposomes
can be considered as an alternative strategy for specific treatment of HER2-positive
breast cancers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.